No Data
No Data
Exact Sciences Reports Launch Of Cologuard Plus Colorectal Cancer Screening Test
Guggenheim Maintains Exact Sciences(EXAS.US) With Buy Rating, Announces Target Price $60
Benchmark Co. Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $65
Exact Sciences Positioned for Growth With Upcoming Product Launches and Margin Expansion
New Analyst Forecast: $EXAS Given $60.0 Price Target
Express News | Exact Sciences Corp : Guggenheim Cuts Target Price to $60 From $73